I-Mab (NASDAQ:IMAB) Shares Sold by Hhlr Advisors LTD.

Hhlr Advisors LTD. lowered its stake in shares of I-Mab (NASDAQ:IMAB) by 13.4% during the fourth quarter, Holdings Channel reports. The fund owned 5,980,568 shares of the company’s stock after selling 928,652 shares during the period. I-Mab comprises 0.2% of Hhlr Advisors LTD.’s investment portfolio, making the stock its 23rd largest position. Hhlr Advisors LTD. owned approximately 0.07% of I-Mab worth $5,083,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Garden State Investment Advisory Services LLC acquired a new position in I-Mab during the 3rd quarter worth $179,000. Institutional investors own 38.38% of the company’s stock.

I-Mab Price Performance

Shares of NASDAQ IMAB opened at $0.81 on Tuesday. The stock’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $0.97. I-Mab has a fifty-two week low of $0.60 and a fifty-two week high of $2.00.

Analyst Upgrades and Downgrades

IMAB has been the topic of a number of analyst reports. Brookline Capital Management raised I-Mab to a “strong-buy” rating in a research report on Thursday, February 27th. HC Wainwright reduced their target price on shares of I-Mab from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $4.00 price target on shares of I-Mab in a report on Friday, April 4th.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.